Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks

Ultragenyx, Regeneron, and Implantica secured FDA approvals for treatments targeting ultra-rare diseases and gastroesophageal reflux, while Lupin gained FDA clearance for a generic sleep disorder drug. IDEAYA and Genentech initiated a clinical collaboration on pancreatic cancer, and BioMarin acquired Alesta in a deal valuing up to $490 million. The biopharma sector showed a mix of regulatory wins, partnerships, and trial setbacks.

This Wire brief sits within Fusion42's coverage of Biotech.